The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.
Clinical trial NCT04514081 · UNKNOWN
Trial details
- NCT number
- NCT04514081
- Sponsor
- Chinese PLA General Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-01
- Primary completion
- 2022-08-01
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.